Cardiol Therapeutics (TSE:CRDL) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Cardiol Therapeutics Inc. successfully held its 2024 Annual General and Special Meeting where shareholders endorsed all management resolutions, including the election of eight directors and the appointment of BDO Canada LLP as auditors. The company, known for its clinical-stage development of heart disease therapies, also received approval for its Omnibus Equity Incentive Plan. Cardiol’s lead drug, CardiolRx™, is progressing through clinical studies with the support of the US FDA.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
